

Predicting New Treatments of Known Drugs Based On Similarity in Changes in Gene Expression

Katie Huang¹, Rachel D. Melamed²

¹ Department of Biomedical Engineering and Biotechnology, University of Massachusetts Lowell ² Department of Biological Sciences, University of Massachusetts Lowell


INTRODUCTION

Drug repurposing offers a quicker and potentially more cost-effective approach to finding new treatments by reusing existing drugs for alternative therapeutic indications. To accelerate the discovery of drug repurposing, the LINCS L1000 project has measured the in vitro effect of hundreds of drugs on gene expression across many cancer cell lines, some with high transcriptional activity scores (TAS) and others with low TAS. Low TAS in samples suggests that the drug has a minimal impact on gene expression, while high TAS indicates that the drug induces significant changes in gene expression.

Gene signature of Drug 1 levels d if high TAS Contained in LINCS L1000 dataset Drug 1 Gene signature iflow TAS MCF7 cell of Drug 1 levels expression

HYPOTHESIS

HYPOTHESIS: If a pair of drugs treat the same disease, and both affect the cell (as measured by TAS), then they may have similar changes in gene expression. Then, we can predict new indications using similarity in gene expression.



METHODS

GENERATE INDIVIDUAL CELL LINE TRAINING DATASETS LINCS L1000 dataset Drug Repurposing Hub **GET PREDICTIONS ON** TAS + gene signatures of drugs Indications of known drugs **CLINICAL TRIALS DATA** (Labelled output) (Input variables) **AACT Database** LINCS L1000 dataset TAS + gene signatures of drugs New experimental PC3 cell line uses of drugs A375 cell line MCF7 cell line PC3 cell line Can Drug 1 Known indication Combine treat indication Generate predictions of Drug 2? A375 cell line predictions on ACROSS all MCF7 cell line clinical trials cell lines TRAIN CELL LINE Drug 2 TAS of Drug 2 Spearman Can Drug 1 treat Drug 2 indication correlation Drug 2 indication? LOGISTIC REGRESSION Labelled **MODELS (LRMs)** output **PREDICTIONS**

lines (MCF7, A375, and PC3), filtering for drugs inducing strong expression changes as measured by transcriptional response (TAS) and known indications recorded in the Drug Repurposing Hub. The spearman

correlation was then computed between drugs and indicated drugs for each indication, using the highest correlation and TAS values to predict indications with logistic regression. Logistic regression models for each

cell line dataset predicted new experimental uses from the AACT database. A weighted ensemble approach was then taken to combine predictions across cell lines by calculating a weighted average of probabilities




Fig 2. Spearman correlation between the changes in gene expression in pairs of drugs that had transcriptional response (TAS > 0.2) for MCF7 cell line. Pairs of drugs that shared at least one indication had more similar changes in gene expression compared to pairs that shared no indications.

Shared Indications

RESULTS Receiver Operating Characteristic (ROC) Curve on Clinical Trials Data Spearman Correlation Between Pairs of Drugs (MCF7 cell line)





Fig 3. ROC curves with AUC scores for individual cell line logistic regression models and the weighted average ensemble model on shared drug indications from clinical trials. The ensemble model exhibited an AUC of 0.72 on all experimental uses.

Contact Information



References

- 1. Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell **171**, 1437-1452.e17 (2017).
- 2. Chen, B. et al. Reversal of Cancer Gene Expression Correlates With Drug Efficacy and Reveals Therapeutic Targets. Nat Commun 8, 16022 (2017).

